Oncology
Positive topline data for Bolt’s BDC-1001 in HER2 solid tumours
US-based biotechnology company Bolt Biotherapeutics has announced positive topline data from a Phase I trial dose-escalation part investigating BDC-1001 in…
MediMergent uses digital clinical trials platform in cancer trial
MediMergent has announced the use of its digital clinical trials platform to collect and analyse real-world data (RWD) in a…
Affimed begins subject dosing in acute myeloid leukaemia therapy trial
Affimed has dosed the first participant in the first-in-human Phase I trial of AFM28 to treat CD123-positive relapsed/refractory (r/r) acute…
Keytruda plus chemotherapy reduce risk of endometrial cancer
Keytruda (pembrolizumab) plus chemotherapy significantly improved progression-free survival (PFS) compared to chemotherapy alone for advanced or recurrent endometrial carcinomas, Merck…
Novartis Phase III Kisqali trial meets primary endpoint of iDFS
Novartis has announced that the Phase III NATALEE trial of Kisqali (ribociclib) and endocrine therapy (ET) met its primary endpoint…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
US FDA releases draft guidance for cancer clinical trials
The US Food and Drug Administration (FDA) has issued draft guidance aimed at improving oncology clinical trials for accelerated approval.…
BridgeBio Pharma starts subject dosing in NSCLC therapy trial
BridgeBio Pharma has dosed the first participant in the Phase I/II clinical trial of BBP-398 in combination with Bristol Myers…
Plus Therapeutics begins leptomeningeal metastases therapy trial
Plus Therapeutics has treated the first participant in Cohort 3 of the Phase I/IIa ReSPECT-LM clinical trial of rhenium (186Re)…
Pipeline Moves: advancement prospects jump for Parkinson’s disease stem cell therapy
This week on Pipeline Moves, we start by looking at completions of Phase II trials in Parkinson’s disease and asthma,…
Shaping AML treatment: how menin inhibitors are changing the game
Syndax Pharmaceuticals and Kura Oncology recently published their fourth-quarter and full-year financial results for 2022. The two biopharmaceutical companies focused…